Influence of smoking and obesity on treatment response in patients with axial spondyloarthritis: a systematic literature review

dc.contributor.authorZurita Prada, Pablo
dc.contributor.authorUrrego Laurín, Claudia
dc.contributor.authorGuillén Astete, Carlos Antonio
dc.contributor.authorKanaffo Caltelblanco, S.
dc.contributor.authorNavarro Compán, Victoria
dc.date.accessioned2021-07-28T16:00:48Z
dc.date.available2021-07-28T16:00:48Z
dc.date.issued2021
dc.description.abstractBackground: Congenital cytomegalovirus infection (CMVc) affects 0.7%-6% of recent births. Among its clinical manifestations are low weight and length at birth. Objective: Describe the growth patterns of children with CMVc in their early years. Methods: Observational, multicenter study of patients with CMVc. Anthropometric data were collected during the first 2 years of life and compared with World Health Organization standards. Results: Anthropometric characteristics of 383 children with CMVc were studied, of which 198 (51%) were symptomatic at birth. At birth, 9% were small for gestational age (SGA) in terms of their weight and length and 17% had microcephaly. At 24 ± 3 months, 10% had a weight and length ≤2 SD, and 13% a head circumference ≤2 SD. Of those who were SGA at birth, at 24 ± 3 months >20% remained at ≤2 SD of their weight and length. Conversely, 75% of children with low weight or length at 24 ± 3 had not been SGA at birth. 20% of infants with microcephaly at birth remained with microcephaly, and 10% of those without microcephaly developed it at 24 ± 3 months. The average growth rate in length and weight was normal. Patients who were symptomatic at birth, premature and with motor and neurocognitive impairment had a significantly higher risk of low weight and length at 24 ± 3 months. Conclusion: Around 10% of children with CMVc are at ≤2 SD in weight, length and head circumference at 24 ± 3 months. The lack of adequate growth is associated with symptoms at birth, prematurity and motor and neurocognitive impairment. Growth impairment could be incorporated into the symptomatic spectrum of CMVc.spa
dc.description.filiationUEMspa
dc.description.impact3.650 JCR (2021) Q3, 20/34 Rheumatologyspa
dc.description.impact0.873 SJR (2021) Q1, 591/2489 Medicine (miscellaneous)spa
dc.description.impactNo data IDR 2021spa
dc.description.sponsorshipSin financiaciónspa
dc.identifier.citationZurita Prada, P., Urrego Laurín, C., Guillén Astete, C. A., Kanaffo Caltelblanco, S., & Navarro Compán, V. (2021). Influence of smoking and obesity on treatment response in patients with axial spondyloarthritis: a systematic literature review. Clinical Rheumatology, 40(5), 1673-1686. https://doi.org/10.1007/s10067-020-05319-6spa
dc.identifier.doi10.1007/s10067-020-05319-6
dc.identifier.issn0770-3198
dc.identifier.issn1434-9949
dc.identifier.urihttp://hdl.handle.net/11268/10261
dc.language.isoengspa
dc.peerreviewedSispa
dc.relation.publisherversionhttp://ezproxy.universidadeuropea.es/login?url=https://doi.org/10.1007/s10067-020-05319-6spa
dc.rights.accessRightsrestricted accessspa
dc.subject.otherEspondiloartritisspa
dc.subject.unescoTabaquismospa
dc.subject.unescoObesidadspa
dc.titleInfluence of smoking and obesity on treatment response in patients with axial spondyloarthritis: a systematic literature reviewspa
dc.typejournal articlespa
dspace.entity.typePublication
relation.isAuthorOfPublication3ce91659-ea76-4a54-a232-84df806bc9d9
relation.isAuthorOfPublicationf66c1f06-c006-4b7a-8f8d-125a879a9c18
relation.isAuthorOfPublication.latestForDiscovery3ce91659-ea76-4a54-a232-84df806bc9d9

Files